Interestingly, among cases where EGFR and KRAS mutation status were known (n = 76), there was a higher YAP1 nuclear staining in EGFR-mutated (n = 16, average H score = 47, positive nuclear YAP1 in 63% of patients) or KRAS-mutated (n = 23, average H score = 51, positive nuclear YAP1 in 65% of patients) lung adenocarcinoma in comparison to EGFR/KRAS wild type (n = 37, average H score = 19, positive nuclear YAP1 in 43% of patients) (P < 0.05) (Figure 5, Table 2). The gene discussed is KRAS; the disease is lung adenocarcinoma.